Network Pharmacology And Case Report Of Taizhong Jifei Drink For The Treatment Of Chronic Duration Of Asthma(Syndrome Of Qi Deficiency Of Lung And Spleen)

Objective:1.To study the effective components,action targets and signaling pathways of Taizhong Jifei Drink in the treatment of asthma through network pharmacological methods and the possible mechanism was discussed in order to provide reference for further research on the mechanism.2.To study the clinical efficacy and safety of Taizhong Jifei Drink in treating patients with chronic duration of asthma(syndrome of Qi deficiency of lung and spleen).Method:1.The active ingredients and targets of Taizhong Jifei Drink were screened using TCMSP and Herb databases,and the asthma disease genes were retrieved using Gene Cards and OMIM databases.The active ingredienttarget-disease network of Taizhong Jifei Drink was constructed using Cytoscape3.9.2.The PPI network was obtained using STRING database.Bioconductor software and R software were used to conduct GO and KEGG enrichment analysis,and Autodock Tools1.5.6 software was used todock the active components and targets.2.70 patients meeting the inclusion criteria were enrolled and divided into control group and treatment group by random number table method.The control group was given basic treatment plus Budesonide and Formoterol Powder for Inhalation(Ⅱ).The treatment group was given Taizhong Jifei Drink orally on the basis of the control group,and the results were statistically analyzed 2 weeks later.The emergency and adverse reactions in the process were also recorded.Results:1.When it comes to the Network pharmacology section,201 active ingredients of Taizhong Jifei Drink were obtained,8172 disease targets were screened,248 intersection targets were found,and potential targets were obtained by the analysis of common target PPI network.The top 10 core targets were IL-6,TP53,EGFR,STAT3,etc.The GO and KEGG analysis showed that the major signaling pathways were TNF,PI3K-Akt,IL-17 and so on.Molecular docking showed that quercetin had good binding activity with AKT1,IL-6 and TNF.2.The total therapeutic response rate of the treatment group was 90.91%;while the control group was 75.76%,moreover,the treatment group was better than the control group(P <0.05).TCM syndrome total score after treatment of the two groups were obviously improved compared with the previous,the control group after treatment for(15.48±6.5),treatment group for(9.36±6.45),greatly lower than the control group(P <0.05).The scores of the two groups were significantly improved(P <0.05).In the treatment group,the symptoms of cough and sputum,wheezing,chest tightness,shortness of breath and fatigue were improved more sharply(P<0.05).Statistically,in regard to spontaneous sweating symptoms,there was no distinction between the two groups.Comparison of single scores of secondary symptoms between the two groups before and after treatment showed that the control group had no statistical differences in hypoglycemia,dilute excrement and the feeling of bulging and fulled about abdomen(P >0.05),while the other symptoms between the two groups before and after treatment showed statistical differences(P <0.05).The results showed that conventional Western medicine had no obvious effect on patients with dysphagia,loose stool and abdominal distension,while the effect of the treatment group had an edge over that of the control group(P <0.05).ACT scores in both groups were greatly increased after treatment(P <0.05),and the increase was more noticeable in the treatment group than in the control group.The t test showed that the lung function(FEV1/FVC、FEV1、PEF)in both groups was improved compared with before treatment(P <0.05).Among the two groups,we found statistical posttreatment distinction(P <0.05),and the effect of the treatment group excelled to that of the control group.FeNO level in both groups was decreased through medical treatment(P <0.05),and the FeNO level in the treatment group was distinctively lower than that in the control group(P <0.05).There were no serious problems in the Various safety indicators throughout the study.Conclusions:1.The results of network pharmacology showed that the microscopic mechanism of action of Taizhong Jifei Drink in the treatment of asthma involves multiple components,multiple targets and multiple signaling pathways,and it can play a therapeutic role through anti-inflammatory,reducing airway hyperreactivity,inhibiting mucus hypersecretion,reducing airway remodeling and injury,and regulating immunity.2.Clinical trials have shown that budesonide and Formoterol combined with Taizhong Jifei Drink can effectively relieve symptoms,improve airflow limitation and reduce FeNO level in the treatment of chronic duration of asthma(syndrome of Qi deficiency of lung and spleen),control disease progression and improve life happiness of patients with asthma,with certain clinical validity and security assurance.